current
pandem
context
propos
valid
effect
treatment
repres
major
challeng
howev
lack
biolog
relev
preclin
experiment
model
infect
complement
classic
cell
line
repres
major
barrier
scientif
medic
progress
advantag
use
human
reconstitut
airway
epitheli
model
nasal
bronchial
origin
character
viral
infect
kinet
tissuelevel
remodel
cellular
ultrastructur
transcript
immun
signatur
induc
result
underlin
relev
model
preclin
evalu
antivir
candid
foremost
provid
evid
antivir
efficaci
remdesivir
therapeut
potenti
remdesivirdiltiazem
combin
rapidli
avail
option
respond
current
unmet
medic
need
impos
biorxiv
preprint
report
advantag
use
physiolog
model
inhous
commerci
avail
reconstitut
human
airway
epithelia
hae
isol
cultur
studi
wide
rang
respiratori
virus
develop
biopsi
nasal
bronchial
cell
differenti
airliquid
interphas
model
reproduc
high
fidel
main
structur
dec
cluster
case
pneumonia
unknown
etiolog
report
wuhan
china
jan
novel
coronaviru
late
name
sever
acut
respiratori
syndrom
coronaviru
classifi
betacoronaviru
genu
identifi
caus
agent
mar
day
world
health
organ
declar
pandem
new
coronaviru
diseas
caus
approxim
death
among
confirm
case
report
mainli
china
also
spread
least
countri
territori
worldwid
compar
two
coronavirus
respons
epidem
outbreak
past
sarscov
merscov
novel
strain
share
genom
sequenc
ident
respect
surprisingli
import
differ
term
epidemiolog
physiopatholog
three
virus
also
observ
emerg
viral
diseas
specif
antivir
treatment
vaccin
three
coronavirus
current
avail
standard
patient
manag
reli
mainli
symptom
treatment
respiratori
support
need
regard
consid
key
featur
biolog
induc
still
requir
character
scarc
readi
biolog
relev
preclin
experiment
model
infect
complement
african
green
monkey
cell
line
repres
major
barrier
scientif
medic
progress
area
other
previous
function
innat
immun
featur
human
respiratori
epithelium
play
central
role
earli
stage
infect
constitut
robust
surrog
studi
airway
diseas
mechan
drug
discoveri
studi
initi
isol
amplifi
cell
viru
directli
form
nasal
swab
one
first
hospit
patient
confirm
franc
complet
genom
sequenc
isol
viru
deposit
gisaid
epicovtm
databas
refer
access
id
phylogenet
analysi
confirm
isol
viru
repres
current
circul
strain
first
character
replic
capac
viral
strain
cell
differ
multipl
infect
moi
fig
use
classic
infecti
titer
determin
cell
cultur
molecular
semiquantit
method
latter
base
primer
probe
design
school
public
healthunivers
hong
kong
detail
supplementari
materi
doubl
approach
facilit
appear
clearli
observ
characterist
cytopath
effect
hpi
fig
enabl
valid
larg
interv
rang
high
correl
rsquar
molecular
infecti
viral
titer
fig
parallel
success
inocul
nasal
hae
apic
surfac
directli
nasal
swab
sampl
confirm
transmiss
electron
microscopi
observ
fig
characterist
featur
coronavirusinduc
cell
ultrastructur
remodel
easili
distinguish
apic
basal
side
hae
hpi
notabl
high
accumul
progeni
virion
mucusproduc
goblet
cell
advantag
exploit
hae
model
inhous
adapt
protocol
previous
optim
differ
respiratori
virus
perform
experiment
infect
viral
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
replic
monitor
repeat
sampl
titrat
apic
surfac
hae
fig
transepitheli
electr
resist
teer
consid
surrog
epithelium
integr
also
measur
timecours
infect
fig
parallel
compar
molecular
viral
genom
quantif
perform
three
level
airliquid
hae
interphas
apic
wash
fig
apic
total
cellular
rna
fig
intracellular
basal
medium
fig
basal
viral
product
epitheli
apic
surfac
increas
sharpli
hpi
reach
nasal
bronchial
hae
respect
peak
viral
replic
reach
earlier
bronchial
hpi
nasal
hae
progress
increas
infecti
viral
titer
observ
least
hpi
fig
replic
kinet
valid
molecular
viral
genom
quantif
apic
pole
fig
high
viral
replic
correl
reduct
epithelium
integr
hpi
reflect
decreas
bronchial
nasal
hae
teer
valu
respect
follow
partial
recoveri
case
bronchial
hae
fig
moreov
viral
product
apic
pole
well
correl
intracellular
viral
genom
detect
infect
except
nasal
hae
hpi
strong
rel
increas
rna
observ
fig
interestingli
viral
genom
detect
basal
medium
hpi
peak
observ
hpi
fig
coincid
highest
impact
infect
epithelium
integr
character
biolog
inocul
nasal
fig
b
bronchial
fig
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
fig
recent
studi
report
high
express
level
cell
receptor
angiotensinconvert
ciliat
goblet
respiratori
cell
previous
observ
structur
studi
coronavirus
notabl
sarscov
merscov
distinguish
characterist
cluster
perinuclear
region
infect
hae
cell
cluster
mainli
compos
numer
viral
singleand
doublemembran
vesicl
dmv
mitochondria
fig
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
hpi
fig
observ
substanti
unsupervis
analysi
data
use
full
gene
panel
inde
first
compon
princip
compon
analysi
pca
account
varianc
mainli
driven
time
infect
clear
discrimin
hpi
timepoint
fig
red
trianglesdot
interestingli
immun
transcriptom
signatur
seem
least
partial
driven
natur
hae
beyond
hpi
fig
agreement
second
compon
analysi
gather
total
varianc
allow
clear
differenti
nasal
bronchial
compart
fig
greenpurpl
triangl
versu
dot
nasal
hae
respons
hpi
peak
hpi
driven
strong
upregul
type
type
iii
ifn
well
immunityrel
gene
wherea
subset
gene
follow
pattern
bronchial
hae
though
overal
lower
express
level
initi
modul
tissu
seem
fade
hpi
moreov
rel
express
subset
gene
associ
nfkb
pathway
eg
nfkbia
tnfa
mostli
unchang
throughout
infect
bronchial
hae
highli
upregul
nasal
hae
hpi
onward
fig
data
taken
togeth
result
highlight
distinct
transcript
immun
signatur
nasal
bronchial
hae
term
kinet
intens
henc
suggest
potenti
intrins
differ
earli
respons
infect
upper
lower
respiratori
tract
result
accord
first
clinic
report
describ
patient
rapid
worsen
respiratori
condit
overal
clinic
state
day
symptom
onset
probabl
relat
cytokin
storm
syndrom
therefor
evalu
hae
model
antivir
potenti
remdesivir
monotherapi
also
combin
diltiazem
diltiazem
voltag
gate
channel
antagonist
current
use
antihypertens
control
angina
pectori
cardiac
arrhythmia
recent
repurpos
effect
hostdirect
influenza
inhibitor
due
far
undescrib
capac
induc
interferon
ifn
antivir
respons
particularli
type
iii
ifn
fig
addit
rational
test
virusdirect
plu
hostdirect
drug
combin
consist
novel
studi
describ
hypertens
potenti
risk
factor
observ
among
cohort
inpati
two
report
anticip
potenti
advers
effect
diltiazem
neg
pharmacolog
interact
remdesivir
diltiazem
treatment
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
diltiazem
monotherapi
experiment
condit
nonetheless
addit
diltiazem
significantli
potenti
antivir
effect
remdesivir
fig
induc
reduct
remdesivir
valu
hpi
respect
compar
daili
treatment
remdesivir
result
reduct
intracellular
viral
titer
hpi
nasal
bronchial
hae
respect
fig
upper
panel
surprisingli
model
complet
function
ifn
respons
daili
treatment
diltiazem
result
moder
yet
substanti
respect
reduct
intracellular
viral
titer
nasal
bronchial
hae
timepoint
fig
upper
panel
top
observ
addit
reduct
nasal
hae
viral
titer
remdesivirdiltiazem
combin
compar
remdesivir
monotherapi
case
antivir
effect
induc
remdesivir
diltiazem
remdesivirdiltiazem
combin
translat
protect
nasal
bronchial
hae
barrier
integr
prevent
drop
teer
valu
induc
infect
fig
lower
panel
importantli
remdesivir
also
show
strong
antivir
effect
hpi
fig
upper
panel
time
reduct
nasal
bronchial
hae
viral
titer
observ
remdesivir
remdesivirdiltiazem
treatment
correl
higher
teer
valu
hae
compart
fig
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
respons
nasal
bronchial
hae
respons
line
viral
replic
kinet
case
other
follow
similar
trend
describ
blood
sampl
patient
cohort
expect
result
provid
start
point
futur
studi
aim
character
local
pathophysiolog
immun
respons
sar
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
